KR20220106642A - Composition for improving hypersensitivity immune disease comprising Swiss chard extract as effective component - Google Patents

Abstract

The present invention relates to a composition containing beetroot extract as an active ingredient and improving hypersensitivity immune disease. Since the active ingredient has an effect of suppressing the secretion of β-hexosaminidase increased by calcium carrier A23187 (Calcium Ionophore A23187), the active ingredient is useful as a composition for preventing, improving or treating allergic atopic dermatitis.

Description

Composition for improving hypersensitivity immune disease comprising Swiss chard extract as effective component

The present invention relates to a composition for improving hypersensitivity immune diseases containing beetroot extract as an active ingredient.

Hypersensitivity immune disease is an immune-mediated disease caused by an overreaction of the normal immune system to non-pathogenic antigens. Hypersensitivity immune response is broadly classified into four types. Among them, type 1 hypersensitivity reaction is generally called allergy, and it is known that there are diseases such as atopic dermatitis, asthma, urticaria, eczema, and hay fever. Allergic reactions are initiated by the binding of antigens to IgE antibodies. Healthy people only produce IgE antibodies against parasitic infections, whereas patients with atopic dermatitis produce IgE antibodies in response to antigens normally present in the environment. IgE antibodies are not destructive by themselves, but when they bind to FcεR receptors that specifically recognize IgE antibodies, they trigger a degranulation process that releases granular components in immune cells, such as mast cells, basophils, and eosinophils, into the blood. The type of granule varies from cell to cell, but generally includes histamine, heparin, beta-hexosaminidase, proteolytic enzyme, and the like. These granule mediators act on surrounding tissues or other immune cells to induce allergic symptoms.

Mast cells are known as key cells that cause acute and chronic inflammatory diseases in most allergic diseases. When mast cells are activated by immunological and pharmacological stimulants such as anti-IgE, calcium transporter (calcium ionophore, A23187), phobol myristate acetate (PMA), inflammatory cytokine, beta-hexosaminidase (β-hexosaminidase) ) and pruritogens. As such, the substances released by mast cells further promote the inflammatory response and at the same time induce the secretion of itch-inducing substances such as histamine, which causes the skin barrier to collapse. Therefore, if a composition capable of suppressing itch mediators without side effects is developed, it will be effective in improving various hypersensitive immune diseases including atopic dermatitis.

Atopic dermatitis is an allergic disease that gets worse in dry climates due to an abnormality in the stratum corneum, which acts as the outermost protective barrier of the skin. Although the cause and mechanism of atopic dermatitis have not yet been precisely elucidated, it is known that mainly immunological and genetic factors are involved. Inflammation accompanying atopic dermatitis is due to the excessive action of immune cells, inflammatory cytokines and activity such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1). Because it mass-produces reactive oxygen species (ROS), it causes damage to surrounding tissues. The prescription for atopic dermatitis is mainly drug therapy such as steroids, antihistamines, and antibiotics. Steroids (corticosteroids) are effective, but side effects such as skin weakness, systemic hormonal symptoms, and addiction may occur if taken for a long period of time. Recently, it has been reported that a magnesium-rich marine mineral solution relieves the symptoms of atopic dermatitis. Therefore, it is expected that a natural extract using salted groundwater, which is known to be rich in minerals, as a solvent, can be a new composition for preventing, improving or treating atopic dermatitis without side effects while being effective against atopic dermatitis.

On the other hand, beetroot ( Beta vulgaris var. cicla L.) is a biennial herb ( Beta vulgaris ) of the Chenopodiaceae family. Stems and leaves are eaten as greens by boiling or fermenting soup, and are rich in vitamin A, vitamin C, and iron.

On the other hand, Korean Patent No. 1793928 discloses 'Anti-aging functional fruit and vegetable beverage containing red beetroot, gold kiwi and strawberry and a manufacturing method thereof', and Korean Patent No. 1045368 discloses 'Anti-aging functional fruit and vegetable beverage containing betanin as an active ingredient'. Although the 'composition for preventing or treating gastrointestinal diseases' has been disclosed, there is no description of the 'composition for improving hypersensitivity immune disease containing beetroot extract as an active ingredient' of the present invention.

The present invention has been derived from the above needs, and provides an anti-atopic composition containing beetroot extract as an active ingredient, and confirms that the beetroot extract inhibits secretion of beta-hexosaminidase By doing so, the present invention was completed.

In order to solve the above problems, the present invention provides a health functional food composition for preventing or improving allergic atopic dermatitis containing beetroot extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating allergic atopic dermatitis containing beetroot extract as an active ingredient.

In addition, the present invention is a cosmetic composition for preventing or improving allergic atopic dermatitis containing beetroot extract as an active ingredient.

The present invention relates to a composition for improving hypersensitivity immune disease containing beetroot extract as an active ingredient, the active ingredient being beta-hexosaminidase secretion increased by calcium transporter A23187 (Calcium Ionophore A23187) Since it has an inhibitory effect, it can be usefully used as a composition for preventing, improving or treating allergic atopic dermatitis.

1 is a result confirming the cytotoxicity in mast cells (RBL-2H3 cells) of beetroot extract. CON is the control group without any treatment. Different letters a to e in the drawing mean that there is a significant difference from each other, and p<0.05.
Figure 2 is the result of confirming the ability to inhibit the production of beta-hexosaminidase (β-hexosaminidase) in mast cells (RBL-2H3 cells) of beetroot extract. CON is a control group that is not treated with anything, A23187 is a beta-hexosaminidase inducer, and EGCG is epigallocatechin gallate. Different letters a to e in the drawing mean that there is a significant difference from each other, and p<0.05.

In order to achieve the object of the present invention, the present invention provides a health functional food composition for preventing or improving allergic atopic dermatitis containing beetroot extract as an active ingredient.

The beetroot extract is preferably an extract using beetroot leaves, but is not limited thereto.

The extract of the present invention is preferably extracted using a C ₁ ~ C ₄ lower alcohol, water, or a mixture thereof as a solvent, and more preferably extracted using ethanol as a solvent, but is not limited thereto.

In one embodiment of the present invention, the extract may inhibit beta-hexosaminidase secretion.

The health functional food composition of the present invention may be in one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup and beverage, but is not limited thereto.

When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The active ingredient may be used appropriately depending on the purpose of its use (prevention or improvement). In general, in the production of food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.

There is no particular limitation on the type of the health functional food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea There are drinks, alcoholic beverages, vitamin complexes, etc., and includes all health foods in the ordinary sense.

In addition, the health functional food composition of the present invention may be prepared as a food, particularly a functional food. The functional food of the present invention may include ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufactured as a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrin, cyclodextrin, etc.) or sugar alcohols (eg, , xylitol, sorbitol, erythritol, etc.). As the flavoring agent, natural flavoring agents (eg, taumatine, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.

In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonic acid It may further contain a carbonation agent and the like used in beverages. The ratio of these added ingredients is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.

In addition, the present invention provides a pharmaceutical composition for preventing or treating allergic atopic dermatitis containing beetroot extract as an active ingredient.

The pharmaceutical composition according to the present invention may be formulated in the form of oral dosage forms such as capsules, powders, granules, tablets, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injection solutions according to conventional methods, respectively. can

Carriers, excipients and diluents that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate, mineral oil, and the like.

In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the pharmaceutical composition, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc. prepared by mixing In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral use include suspensions, solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc. in addition to water and liquid paraffin, which are commonly used simple diluents, may be included. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, Witepsol, Macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, etc. may be used.

A suitable dosage of the pharmaceutical composition of the present invention may be prescribed variously depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity of the patient. can

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by topical application to the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.

In addition, the present invention provides a cosmetic composition for preventing or improving allergic atopic dermatitis containing beetroot extract as an active ingredient.

In the cosmetic composition for preventing or improving allergic atopic dermatitis of the present invention, the cosmetic composition is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation , emulsion, foundation, wax foundation, and spray, preferably in any one formulation, more preferably external skin ointment, cream, softening lotion, nourishing lotion, pack, essence, hair tonic, shampoo, conditioner, hair conditioner , hair treatment, gel, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, eye cream, moisture cream, hand cream, foundation, nourishing essence, sun It may have any one formulation selected from the group consisting of screen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto. The composition of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.

When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc acid may be used as a carrier component. can When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether. When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.

When the formulation of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used. When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.

Hereinafter, the present invention will be described in more detail using Preparation Examples and Examples. These preparations and examples are only for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.

Preparation Example 1. Preparation of beetroot extract

Beetroot was grown in Icheon, Gyeonggi-do in October 2017, and was purchased from Homeplus Co., Ltd. After drying the chard by air at 40° C. for 48 hours and pulverizing it with a dry grinder (Hanil-HME-60, Korea), chard powder was prepared using a 50 mesh sieve. 50 ml of 70% (v/v) ethanol was added to 5 g of the chard powder, extracted with stirring at 180 rpm for 3 hours at room temperature, and the supernatant obtained by centrifugation at 12,000 rpm for 10 minutes using 0.45 μm filter paper The chard extract was prepared by filtration.

The beetroot extract was taken in an aluminum dish and dried at 60° C. for 3 hours, 85° C. for 30 minutes, and 90° C. for 30 minutes, and then the weight was measured. Then, the extraction yield (%) was calculated by substituting the following formula.

Extraction yield (%)={(weight after drying)/(weight of powder used before extraction)}×100

As a result, it was confirmed that the extraction yield of the beetroot extract was 27.0%.

Example 1. Measurement of cytotoxicity

Mast cells (RBL-2H3, Rat Basophil Leukemia) were purchased from ATCC (American Type Culture Collection, USA), and DMEM containing 10% fetal bovinwe serum (FBS) and penicillin (100 IU/ml) Dulbecco's Modified Eagle Medium) medium was used at 37° C., and cultured in a cell incubator under 5% CO ₂ conditions.

In a 96-well plate for cell culture, RBL-2H3 cells were seeded at 4×10 ⁴ cells/well and cultured for 24 hours, then treated with 25 μg/ml, 50 μg/ml and 100 μg/ml of beetroot extract and 24 incubated for hours. Thereafter, 5 mg/ml of MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide) reagent was added to each well and incubated for 3 hours, the supernatant was removed and 100 μl of DMSO (dimethyl sulfoxide) was added to dissolve formazan crystals, and absorbance was measured at 570 nm using a microplate reader. For cytotoxicity, the relative cell viability of the beetroot extract treated group was calculated with the survival rate of the untreated group being 100%.

As a result, it was confirmed that 25㎍ / ㎖, 50㎍ / ㎖, and 100㎍ / ㎖ of beetroot extract does not show cytotoxicity in mast cells (Fig. 1).

Example 2. Beta-hexosaminidase (β-hexosaminidase) secretion inhibitory ability measurement

To analyze the inhibitory effect of beetroot extract on allergic reaction, beta-hexosaminidase degranulation amount in mast cells was measured.

In a 24-well plate for cell culture, mast cells (RBL-2H3 cells) were seeded at 4×10 ⁵ cells/well and cultured for 24 hours, and then, in order to induce beta-hexosaminidase production, 1 μM calcium carrier A23187 (Calcium Ionophore A23187) was treated, and 25 μg/ml, 50 μg/ml and 100 μg/ml of beetroot extract were added and reacted for 1 hour. Then, 1 mM substrate (4-nitrophenyl N-acetyl-β-D-glucosaminide dissolved in 0.05 M citrate buffer (pH 4.5)) was reacted for 1 hour, and a stop reagent (0.1 M carbonate buffer) was added and reacted. After termination, the absorbance was measured at 405 nm. Epigallocatechin gallate (EGCG), which is known to have an anti-allergic effect, was used as a positive control.

As a result, it was confirmed that the beetroot extract decreased the secretion of beta-hexosaminidase increased by the calcium transporter A23187 (FIG. 2).

Claims (5)

A health functional food composition for preventing or improving allergic atopic dermatitis containing beetroot extract as an active ingredient. According to claim 1, wherein the solvent of the extract is C ₁ ~ C ₄ Health functional food composition for the prevention or improvement of allergic atopic dermatitis, characterized in that the lower alcohol, water, or a mixture thereof. The health functional food composition for preventing or improving allergic atopic dermatitis according to claim 1, wherein the extract inhibits the secretion of beta-hexosaminidase. A pharmaceutical composition for preventing or treating allergic atopic dermatitis containing beetroot extract as an active ingredient. A cosmetic composition for preventing or improving allergic atopic dermatitis comprising beetroot extract as an active ingredient.

Images